Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of PRX019 in Healthy Adults
NCT06699680Phase 1Completed
- Sponsor
- Prothena Corporation
- Start
- Nov 2024
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PRX019 (2 arms), sponsored by Prothena Corporation. Primary endpoints: Number of participants with adverse events at 6 months and Number of participants with clinical laboratory assessment abnormalities at 6 months. Started Nov 2024; status: completed.
02
Drugs
PRX019
Beyond the preview
Go deeper on NCT06699680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06699680.